Mersana Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview
11/11/2024 15:38
* Mersana Therapeutics Inc MRSN.OQ MRSN.O is expected
to show
a fall in quarterly revenue when it reports results on November
13 for the period ending September 30 2024
* The Cambridge Massachusetts-based company is expected to
report
a 2.2% decrease in revenue to $7.53 million from $7.7 million a
year ago, according to the mean estimate from 10 analysts, based
on LSEG data.
* LSEG's mean analyst estimate for Mersana Therapeutics Inc
is
for a loss of 18 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Mersana
Therapeutics Inc is $7.00, above its last closing price
of $2.57.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jan. 1 0001 -0.17 -0.17 -0.20 Missed -16.7
Jan. 1 0001 -0.18 -0.18 -0.16 Beat 11.6
Dec. 31 2023 -0.12 -0.16 -0.16 Met 2.6
Sep. 30 2023 -0.35 -0.36 -0.27 Beat 25.4
Jun. -0.37 -0.44 -0.47 Missed -6.5
30 2023
Mar. 31 2023 -0.40 -0.44 -0.52 Missed -19.3
Jan. 1 0001 -0.47 -0.50 -0.44 Beat 12.8
Jan. 1 0001 0.04 -0.09 -0.61 Missed -577.8
This summary was machine generated November 11 at 15:38 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)